{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"13"}],"units":"Participants"}],"groups":[{"description":"Cohort 1: Total Bone Marrow Irradiation (TBMI): 8 Gy delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3.\n\nMelphalan 140 mg/m² infused intravenously during 30 minutes on day -2 after IV anti-emetics.\n\nAutologous Peripheral Stem Cell Rescue : re-infused in the central line on day \"0\" after adequate premedication.","id":"BG000","title":"Total Bone Marrow Irradiation (TBMI): 8 Gy"},{"description":"Cohort 2: Total Bone Marrow Irradiation (TBMI): 10 Gy delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3.\n\nMelphalan 140 mg/m² infused intravenously during 30 minutes on day -2 after IV anti-emetics.\n\nAutologous Peripheral Stem Cell Rescue : re-infused in the central line on day \"0\" after adequate premedication.","id":"BG001","title":"Total Bone Marrow Irradiation (TBMI): 10 Gy"},{"description":"Cohort 3: Total Bone Marrow Irradiation (TBMI): 12 Gy delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3.\n\nMelphalan 140 mg/m² infused intravenously during 30 minutes on day -2 after IV anti-emetics.\n\nAutologous Peripheral Stem Cell Rescue : re-infused in the central line on day \"0\" after adequate premedication.","id":"BG002","title":"Total Bone Marrow Irradiation (TBMI): 12 Gy"},{"description":"Cohort 4: Total Bone Marrow Irradiation (TBMI): 14 Gy delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3.\n\nMelphalan 140 mg/m² infused intravenously during 30 minutes on day -2 after IV anti-emetics.\n\nAutologous Peripheral Stem Cell Rescue : re-infused in the central line on day \"0\" after adequate premedication.","id":"BG003","title":"Total Bone Marrow Irradiation (TBMI): 14 Gy"},{"description":"Cohort 5: Total Bone Marrow Irradiation (TBMI): 16 Gy delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3.\n\nMelphalan 140 mg/m² infused intravenously during 30 minutes on day -2 after IV anti-emetics.\n\nAutologous Peripheral Stem Cell Rescue : re-infused in the central line on day \"0\" after adequate premedication.","id":"BG004","title":"Total Bone Marrow Irradiation (TBMI): 16 Gy"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"13"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"13"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"8"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"13"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG005","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"1"},{"groupId":"BG005","value":"13"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"13"}],"units":"Participants"}],"title":"France"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"Participants"}],"populationDescription":"The study was terminated prematurely, due to a lack of enrolments"}